Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/CIRCULATIONAHA.124.068018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk-Based Screening of Atrial Fibrillation in General Practice (R-BEAT): A randomised Cross-over Trial.
QJM
January 2025
HRB Clinical Research Facility Galway, School of Medicine, University of Galway, Galway, Ireland.
Background: The optimal approach to the diagnosis of atrial fibrillation in primary care is unclear.
Aim: To determine if external loop recorder (ELR) screening improves atrial fibrillation detection in community dwelling adults with a CHA2DS2-VASc score of greater than two.
Design: Randomised cross-over clinical trial.
Arterial Thromboembolism in Patients With Advanced Lung Cancer: Secondary Analyses of the Rising-VTE/NEJ037 Study.
Cancer Med
January 2025
Division of Medical Oncology and Respiratory Medicine, Department of Internal Medicine, Shimane University Faculty of Medicine, Izumo, Japan.
Background: Cancer-associated thromboembolism has been thoroughly investigated in previous studies, and direct oral anticoagulants (DOACs) were established for the treatment and prevention of venous thromboembolism (VTE). However, the risks of cancer-associated arterial thromboembolism (ATE) and the efficacy of DOACs remain unclear.
Objectives: To evaluate the risk factors and the clinical activity of edoxaban (EDO) for the prevention of ATE in patients with advanced lung cancer.
Background: ALZ-801/valiltramiprosate, an oral small molecule inhibitor of amyloid oligomer formation, is being evaluated in a Phase 3 trial in APOE4/4 Early AD subjects (APOLLOE4). Topline results are expected in 3Q 2024. APOE4 is a major risk factor for Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA) with a gene-dose effect.
View Article and Find Full Text PDFRelated factors and safety of reaching the therapeutic target of warfarin after heart valve surgery in hospitalized patients: A retrospective cohort study.
Exp Ther Med
February 2025
Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450001, P.R. China.
Warfarin is a commonly employed anticoagulant drug aimed at rapidly reaching the optimal international normalized ratio (INR), potentially reducing the hospitalization time in clinical settings. However, limited research has been conducted on the influencing factors and the safety implications of promptly reaching the target INR range in patients with valvular heart disease who have undergone valve replacement or repair. The present study aimed to assess the factors related to the safety considerations of rapidly reaching the target INR range in patients treated with warfarin.
View Article and Find Full Text PDFDevelopment and validation of a five-year cardiovascular risk assessment tool for Asian adults aged 75 years and older.
BMC Geriatr
January 2025
Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, No. 33, Linsen S. Rd., Zhongzheng Dist., Taipei, 100025, Taiwan.
Background: To identify cardiovascular (CV) risk factors in Asian elderly aged 75 years and older and subsequently develop and validate a sex-specific five-year CV risk assessment tool for this population.
Methods: This study included 12,174 patients aged ≥ 75 years without a prior history of cardiovascular disease at a single hospital in Taiwan. Electronic health records were linked to the National Health Insurance Research Database and the National Death Registry to ensure comprehensive health information.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!